Intellectual Property (IP) is often an emerging biotech company’s most valuable asset. IP can define a company’s ability to compete in the marketplace and is key to support funding rounds, partnerships and the company’s ultimate success.
In this Forum, industry experts will share critical advice for entrepreneurs who are setting out to acquire their IP. Our panelists will address key IP topics such as:
- Traditional routes of IP acquisition – including licensing from a university, e.g. the employer of a scientific founder
- Licensing arrangements – often the first contractual relationships into which the emerging biotech company enters
- How universities have changed their approaches to technology transfer and licensing terms in recent years – including an increased focus on revenue, especially in light of declining government research funding
- Alternatives to university deals – for example, some companies have succeeded in “rescuing” assets from big pharma through in-licensing assets that have been shelved
- Generating an IP portfolio – when, what and how entrepreneurs, scientists and biotech leaders should manage this important part of their IP expansion strategy
Boston IP associate, Stephen Altieri, will be co-moderating this event.
Please note, this event is for Mass Biotech Council members only.